2014
DOI: 10.1016/j.pupt.2014.05.008
|View full text |Cite
|
Sign up to set email alerts
|

Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
24
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 29 publications
(24 citation statements)
references
References 266 publications
0
24
0
Order By: Relevance
“…Human lung exposure to deleterious effects of metal can result to pulmonary fibrosis . Moreover, long‐term inflammation of the lung by metals destroyed the alveolar walls .…”
Section: Introductionmentioning
confidence: 99%
“…Human lung exposure to deleterious effects of metal can result to pulmonary fibrosis . Moreover, long‐term inflammation of the lung by metals destroyed the alveolar walls .…”
Section: Introductionmentioning
confidence: 99%
“…Members of the TRP channel family have been implicated in a number of critical phagocytic functions, including particle uptake, migration, and reactive oxygen species (ROS) production (5,(8)(9)(10)(11). Numerous studies (12)(13)(14)(15) have suggested TRP channels as potential targets for the development of therapies in pulmonary inflammation because of their abundant and diverse cellular expression throughout the respiratory tree. Although TRPC6 channels have been previously identified in lung macrophages and shown to be up-regulated in COPD, their precise role in the pathophysiology of the disease is yet to be determined (16).…”
mentioning
confidence: 99%
“…Clinically, COPD are not easily treated with currently available drugs that include antitussives, cholinergics, bronchodilators, and anti‐inflammatory steroids (Jeffery, ). Even treatments with recently developed anti‐cytokine agents, leukotriene receptor antagonist, and phosphodiesterase 4 inhibitor can only provide limited success (Baker et al, ). Because the etiology and progress of COPD are complex, pinpointing the appropriate molecular target(s) that can obviate symptoms and progress of COPD has been challenging (Barnes, ).…”
Section: Introductionmentioning
confidence: 99%